Coherus Oncology, Inc. Common Stock
CHRSStock
$1.39+69.61%52W
Market Cap$222.12M
P/E1.32x
Div yield—
Beta0.93
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.76%
Price vs S&P 500 (4W)3.75%
VGM Score54.27
Market Capitalization$222.12M
P/E Ratio (Annual)1.32x
Earnings Surprise History
Q1 26-0.25est. -0.28
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.17
4.17
4.23
4.23
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CHRSCoherus Oncology, Inc. Common Stock | B | C | C | $1.39 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Coherus Oncology is a commercial-stage biotechnology company with LOQTORZI, an approved PD-1 inhibitor, and a pipeline of two mid-stage clinical candidates. The company is expanding LOQTORZI's use in nasopharyngeal cancer and exploring combination therapies with its pipeline candidates and industry partners. Key assets include LOQTORZI, CHS-114, and Casdozokitug, targeting liver, lung, head and neck, and other cancers.